As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Hallmeyer was a presenter of the day 1 workshop, “Precision Medicine,” at the 49th Association of Community Cancer Centers’ 49th Annual Meeting and Cancer Center Business Summit.
Transcript
What are some best practices clinics can utilize to identify patients suitable for a precision medicine course of treatment?
The current indications for the medications that have been approved in the setting of oncology, that are based on precision medicine and molecular testing, have really been established in the advanced-stage setting: stage IV, metastatic disease, and oftentimes in lines that have exceeded standard of care. So when patients are believed to no longer benefit from standard of care is when typically these molecular studies are ordered and then the more experimental therapies are being utilized in that setting.
That is changing, though, as we are identifying these targets in patients in the later-stage settings that could potentially make a significant impact if we were to utilize the medications that are attached to these molecular alterations sooner in the trajectory. And so in that, you’re identifying a bit of a shift in when physicians actually utilize, for instance, next-generation sequencing, where there’s, probably more now, a push in using that earlier and earlier in the trajectory of the disease. And I would say probably in the majority of practices now, these are done in the first-line setting when patients are ultimately identified with advanced disease or stage IV disease.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More